Skip To Main Content
Francina Agosti on Muck Rack

Francina Agosti

Verified
(She/Her)
Genoa, Italy
As seen in: BrightFocus Foundation, European Biotechnology, Labiotech, Big Think, BioRxiv, EIN News, NewsBreak, The Journal of Clinical Investigation, Advanced Science News, Freethink, Drug Discovery News (DDN), Exosome RNA
Covers:  biotech, science, life science, clinical trials, research news
Divorced from academia, dating biotech writing, having an affair with science news🔭 When not writing, I'm walking my dog in the ⛰️ agfrancina@gmail.com 📩

Get in touch with Francina

Contact Francina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Francina Agosti’s Biography

Read Full Bio →

Biotech and science freelance writer, former neuroscientist, forever nerd.

I enjoy translating complex scientific discoveries and medical data into engaging and understandable copy to educate the general public, scientists, and investors.

Articles

Inside exosomes: Nature’s drug carriers

|
By Francina Agosti Verified
| European Biotechnology Verified
Picture: A. C. for Unsplash Imagine a payload being delivered to the target tissue by a biological, non-toxic transport system. Imagine a drug traveling to the central nervous system without the need for invasive injections or without side effects caused by its untargeted, undesirable reach. Imagine a payload reaching the intended cells through a mechanism that is natural, that can be administered more than once, and is adaptable across applications.
Open in Who Shared Issue with article?

ESC 2026: Five stories that mattered in Munich

|
By Francina Agosti Verified
| European Biotechnology Verified
Photo by jesse orrico on Unsplash 1. Cytokinetics: first-ever targeted therapy benefit in nonobstructive HCM The news was so big that one section wasn’t enough. During one of Friday’s Hot Line sessions and a Saturday’s Late Breaking Clinical Trial session, Cytokinetics shared detailed data from its phase 3 trial for Myqorzo (aficamten), a cardiac myosin inhibitor, in non-obstructive hypertrophic cardiomyopathy (nHCM).
Open in Who Shared Issue with article?

Tetrahedral DNA frame delivers RNA to joints for osteoarthritis treatment

|
By Francina Agosti Verified
| Advanced Science News Verified
Biotechnology | Health | Therapeutics A DNA carrier with RNA incorporated into its vertices overcomes the problem of delivering treatments into joints for osteoarthritis patients. Osteoarthritis affects over 500 million people worldwide—and those numbers are expected to double by 2050—and still there is no medicine that specifically treats the disease itself. One reason is that osteoarthritis is highly complex.
Open in Who Shared Issue with article?
See all 86 articles